REMARKS

The Examiner has required a species election under 35 U.S.C. § 121 of one of the following particular types of peripheral T-cell lymphoma: adult T-cell leukemia, large granular lymphocyte leukemia, angioimmunoblastic T-cell lymphoma, intestinal T-cell lymphoma, anaplastic large cell lymphoma, nasal and nasal type NK/T-cell lymphoma, peripheral T-cell lymphoma unspecified, or hepatosplenic gamma/delta T-cell lymphoma. In response, Applicants hereby elect adult T-cell leukemia as the species of peripheral T-cell lymphoma.

The Examiner has also required an election under 35 U.S.C. § 121 of one of the following particular types of method of treating a T-cell malignancy from the group: a method of treating a T-cell malignancy refractory or non-responsive to chemotherapy, or a method of treating a T-cell malignancy wherein the human has not been previously treated for the T-cell malignancy. In response, Applicants hereby elect a method of treating a T-cell malignancy refractory or non-responsive to chemotherapy as a particular species of method of treating a T-cell malignancy.

Applicants believe that claims 45-67, 70-79, and 82 read on the elected invention. Entry of the remarks made herein is respectfully requested.

Respectfully submitted,

Date:

November 13, 2007

. .

35,203

Anthony M. Insbgna

(Keg. No.)

Ø/5

3y: Jemiter

222 East 41st Street

New York, New York 10017-6702

(212) 326-3939

JONES DAY